Search

Prema Maria Mertz

Examiner (ID: 426, Phone: (571)272-0876 , Office: P/1646 )

Most Active Art Unit
1646
Art Unit(s)
1674, 1646, 1621, 1812
Total Applications
2681
Issued Applications
1589
Pending Applications
444
Abandoned Applications
675

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17895442 [patent_doc_number] => 20220305104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => METHODS OF TREATING ATOPIC DERMATITIS [patent_app_type] => utility [patent_app_number] => 17/696028 [patent_app_country] => US [patent_app_date] => 2022-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17696028 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/696028
Methods of treating atopic dermatitis Mar 15, 2022 Issued
Array ( [id] => 17734720 [patent_doc_number] => 20220220179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => FUSION PROTEIN COMPRISING IL13 [patent_app_type] => utility [patent_app_number] => 17/693956 [patent_app_country] => US [patent_app_date] => 2022-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -223 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17693956 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/693956
Fusion protein comprising IL13 Mar 13, 2022 Issued
Array ( [id] => 17867099 [patent_doc_number] => 20220289834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody [patent_app_type] => utility [patent_app_number] => 17/691219 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17691219 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/691219
Method of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL23 specific antibody Mar 9, 2022 Issued
Array ( [id] => 20336505 [patent_doc_number] => 20250340625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2, OR FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 18/556651 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556651 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/556651
ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2, OR FRAGMENT THEREOF Mar 9, 2022 Pending
Array ( [id] => 19809518 [patent_doc_number] => 12240889 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Decoy cytokine receptor [patent_app_type] => utility [patent_app_number] => 17/687554 [patent_app_country] => US [patent_app_date] => 2022-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 75 [patent_no_of_words] => 29462 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17687554 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/687554
Decoy cytokine receptor Mar 3, 2022 Issued
Array ( [id] => 19491647 [patent_doc_number] => 12110343 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-08 [patent_title] => Anti-plasma kallikrein antibodies [patent_app_type] => utility [patent_app_number] => 17/684460 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 5 [patent_no_of_words] => 13930 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684460 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/684460
Anti-plasma kallikrein antibodies Mar 1, 2022 Issued
Array ( [id] => 17672711 [patent_doc_number] => 20220185878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => BIOPHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/684907 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684907 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/684907
Biopharmaceutical compositions Mar 1, 2022 Issued
Array ( [id] => 17830125 [patent_doc_number] => 20220267429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS [patent_app_type] => utility [patent_app_number] => 17/684305 [patent_app_country] => US [patent_app_date] => 2022-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684305 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/684305
Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders Feb 28, 2022 Issued
Array ( [id] => 19425078 [patent_doc_number] => 12084481 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => HV1 modulators and uses [patent_app_type] => utility [patent_app_number] => 17/684346 [patent_app_country] => US [patent_app_date] => 2022-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 35 [patent_no_of_words] => 21839 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684346 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/684346
HV1 modulators and uses Feb 28, 2022 Issued
Array ( [id] => 19217893 [patent_doc_number] => 20240182597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES [patent_app_type] => utility [patent_app_number] => 18/547663 [patent_app_country] => US [patent_app_date] => 2022-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18547663 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/547663
ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES Feb 27, 2022 Pending
Array ( [id] => 20756214 [patent_doc_number] => 12648963 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-09 [patent_title] => MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function [patent_app_type] => utility [patent_app_number] => 18/546936 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 84 [patent_no_of_words] => 22351 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546936 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/546936
MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function Feb 17, 2022 Issued
Array ( [id] => 17655454 [patent_doc_number] => 20220175919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => THERAPEUTIC AGENTS FOR PANCREATIC CANCER [patent_app_type] => utility [patent_app_number] => 17/674989 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9253 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674989 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/674989
THERAPEUTIC AGENTS FOR PANCREATIC CANCER Feb 17, 2022 Abandoned
Array ( [id] => 20756214 [patent_doc_number] => 12648963 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-09 [patent_title] => MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function [patent_app_type] => utility [patent_app_number] => 18/546936 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 84 [patent_no_of_words] => 22351 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546936 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/546936
MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function Feb 17, 2022 Issued
Array ( [id] => 19112837 [patent_doc_number] => 20240124587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => MULTI-DOMAIN FUSION PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/277996 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10997 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277996 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/277996
MULTI-DOMAIN FUSION PROTEIN AND USE THEREOF Feb 16, 2022 Pending
Array ( [id] => 19020190 [patent_doc_number] => 20240076361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ANTI-PT217 TAU ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/273355 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273355 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/273355
ANTI-PT217 TAU ANTIBODY Feb 16, 2022 Pending
Array ( [id] => 19563545 [patent_doc_number] => 12138296 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Formulations for bovine granulocyte colony stimulating factor and variants thereof [patent_app_type] => utility [patent_app_number] => 17/591553 [patent_app_country] => US [patent_app_date] => 2022-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14272 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17591553 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/591553
Formulations for bovine granulocyte colony stimulating factor and variants thereof Feb 1, 2022 Issued
Array ( [id] => 17611532 [patent_doc_number] => 20220153811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => Advanced Avatar Dendritic Cells [patent_app_type] => utility [patent_app_number] => 17/588949 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10003 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17588949 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/588949
Advanced avatar dendritic cells Jan 30, 2022 Issued
Array ( [id] => 17734736 [patent_doc_number] => 20220220195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => ANTIBODY TO HUMAN IL-1 BETA [patent_app_type] => utility [patent_app_number] => 17/587751 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587751 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/587751
ANTIBODY TO HUMAN IL-1 BETA Jan 27, 2022 Abandoned
Array ( [id] => 19396145 [patent_doc_number] => 12070474 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-27 [patent_title] => Methods and compositions for natural killer cells [patent_app_type] => utility [patent_app_number] => 17/585126 [patent_app_country] => US [patent_app_date] => 2022-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 13 [patent_no_of_words] => 14469 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17585126 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/585126
Methods and compositions for natural killer cells Jan 25, 2022 Issued
Array ( [id] => 17734724 [patent_doc_number] => 20220220183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF DISEASES [patent_app_type] => utility [patent_app_number] => 17/583971 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583971 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/583971
Compositions and methods relating to the treatment of diseases Jan 24, 2022 Issued
Menu